NextBioMedical Co

NextBioMedical Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is 611.27 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -57.35 % — a change of -1,165.86% (higher).

FCF Conversion

611.27 %

YoY

-1,165.86%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of NextBioMedical Co is 2025 611.27 % . FCF Conversion Rate (FCF/EBITDA) of NextBioMedical Co was 2024 -57.35 % . It decreases by -1,165.86% higher compared to the previous year.

The NextBioMedical Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
37.07 KRW
Jan 1, 2022
146.61 KRW
Jan 1, 2023
56.17 KRW
Jan 1, 2024
-57.35 KRW
Jan 1, 2025
611.27 KRW
The NextBioMedical Co FCF Conversion history
YEARFCF ConversionYoY
611.27 %-1,165.86%
-57.35 %-202.11%
56.17 %-61.69%
146.61 %+295.47%
37.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

FCF Conversion Rate (FCF/EBITDA) of NextBioMedical Co is 611.27 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of NextBioMedical Co changed from -57.35 % to 611.27 %, representing a -1,165.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s NextBioMedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — NextBioMedical Co

All Key Metrics — NextBioMedical Co